Once-Weekly Basal Insulin Awiqli
Health · Friday, 10 July 2026
Novo Nordisk launched Awiqli, a once-weekly insulin for diabetes management.
Quick highlights
- First once-weekly insulin approved in India.
- Reduces injection burden significantly.
- Improves blood sugar management.
Context
Launch of Awiqli in India by Novo Nordisk.
Key Facts
Awiqli is a long-acting insulin analogue.
Significance
Encourages early treatment initiation for diabetes.
Challenges / Way Forward
Ensuring affordability and accessibility.
Exam Angle
Relevant for GS Paper II on Health.
Remember this
- Awiqli reduces yearly injections from 365 to 52.
- Improves glycemic control without hypoglycemia.
- Marketed through pre-filled pens.
- Encourages competition in insulin therapies.